Thoratec Corp. reported third-quarter sales of $87.9 million during the three months ended Oct. 3, up 8.8 percent compared with $80.8 million during the same year. Net income soared 94.4 percent to $11.8 million, compared with $6.1 million during Q3 2008:
MassDevice Earnings Roundup
NxStage Medical Inc. rode big gains in its home dialysis and critical care businesses to narrow losses by more than 30 percent during the three months ended Sept. 30.
The Lawrence, Mass.-based dialysis maker said sales jumped 27 percent during the quarter to $38 million, compared with $30 million for the same period last year. The robust sales exceeded even management’s expectations of revenues of up to $35 million.
Viking Systems Inc. reported third-quarter sales of $2 million during the three months ended Sept. 30, up 25.8 percent compared with $1.6 million during the same period last year. Net losses widened from $43,600 to $195,900, a 350 percent jump, but operating losses slid 81.5 percent to $193,300, compared with $1 million during the year-ago quarter:
Sales slumped and net losses grew during the third quarter for NeuroMetrix Inc., as hospitals kept less of its nerve testing consumables on hand.
The Waltham, Mass.-based company posted sales of $6.3 million during the three months ended Sept. 30, down 10.6 percent compared with $7.1 million during the same period last year. Net losses widened 18 percent to $9.3 million, compared with $7.9 million during the third quarter of 2008.
The Framingham, Mass., manufacturer of militarized heart pumps began limited sales late last year, after receiving an investigational device exemption from U.S. regulators in Sept. 2008. That means a comparison year-over-year results is misleading, as total 2008 sales reached only $332,000.
The HeartWare Ventricular Assist System was approved for commercial sales throughout most of Europe in January.
Sales of Abiomed Inc.‘s Impella cardiac assist device continued to grow during the fiscal 2010 second quarter, but sales were flat and net losses widened by 21.2 percent.
The Danvers, Mass.-based company posted sales of $20 million during the three months ended Sept. 30, flat compared with the same number during the second quarter of fiscal 2009. Net losses for the quarter gapped to $7.7 million, compared with $6.3 million during Q2 2009.
Staar Surgical Co. posted net losses of $2 million on sales of $18.1 million during the third quarter:
STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter
Largest Amount of Cash from Operating Activities in More Than Six Years
Domestic Operating Expenses Down and Gross Margins Up
Global Visian ICL(R) Sales Increase Five Percent
Global IOL Sales Grow Seven Percent
CAST Project Surpasses 300 Eyes; nanoFLEX(TM) Marketing to Increase in U.S.
Masimo Reports Third Quarter 2009 Financial Results
Q3 2009 Highlights:
– Product revenues increased 14% to $75.1 million from $66.1 million in prior year
– Rainbow revenues increased approximately 100% to $6.0 million from $3.0 million in prior year
– Shipped 26,200 Masimo SET and Masimo Rainbow SET pulse oximetry units
Solta Medical Inc. posted third-quarter sales and earnings results and issued its full-year guidance for fiscal 2009:
HAYWARD, Calif., Nov. 3 /PRNewswire-FirstCall/ — Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced results for the third quarter ended September 30, 2009. Revenue for the quarter was in-line with the preliminary forecast provided on September 28th.
Becton, Dickinson & Co. posted net income of $1.23 billion on sales of $7.16 billion during fiscal 2009, up 9.3 percent and 1.2 percent, respectively, compared with net income of $1.13 billion on $7.07 billion in revenues last year.
The Franklin Lakes, N.J.-based medical device leviathan said fourth-quarter sales reached $1.9 billion, up 4.7 percent compared with $1.81 billion during the same period last year, with Q4 net income rising 12.4 percent to $317.2 million, compared with $282.2 million during the 2008 fourth quarter.
Hurt by a slump in its drug-testing services business and continuing restructuring costs, profits for Charles River Laboratories International Inc. fell 18 percent during its September quarter.